– UK, Watford – Smith+Nephew PLC (LON: SN | NYSE: SNN), the global medical technology business, today announced the appointment of Bob White as a Non-Executive Director.
Bob is a proven MedTech leader with more than 25 years’ experience spanning the US, Europe and Asia Pacific. He is currently Executive Vice President and President, Minimally Invasive Therapies Group and a member of the Executive Committee for Medtronic plc.
Bob will join the Board on 1 May 2020.
“The Board believes it is important that we include a Non-Executive Director with a deep knowledge of the global MedTech space. Bob is a well-regarded and influential member of our industry who brings both a large company perspective and the experience of working in the US, our largest market, and Asia Pacific, a vital growth opportunity for Smith+Nephew. We are delighted to have Bob join the Board.” said Roberto Quarta, Chair of Smith+Nephew.
About Bob White
Bob previously served as Senior Vice President and President of Medtronic Asia Pacific, having led the integration of Covidien Asia Pacific when it was acquired by Medtronic in 2015. At Covidien, he served in a number of increasingly senior roles including President, Emerging Markets and President, Respiratory and Monitoring Solutions. He has also held leadership positions at GE Healthcare and IBM.
Bob is a Fellow of the American College of Healthcare Executives. He holds a bachelor’s degree in marketing from Cleveland State University and an MBA from Case Western Reserve University.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,500+ employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE: SN | NYSE: SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries unless the context requires otherwise.
For more information: https://www.smith-nephew.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
